Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
20,326
Total Claims
$1.5M
Drug Cost
1,595
Beneficiaries
$957
Cost/Patient
Risk Score Breakdown 15/100
Score components are additive. Read full methodology
Peer Comparison vs. 7,389 General Practice providers
-61%
Opioid rate vs peers
1.0% vs 2.5% avg
-15%
Cost per patient vs peers
$957 vs $1,128 avg
+30%
Brand preference vs peers
10.9% vs 8.4% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
🔎 Data Overview
This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Opioid Prescribing
1.0%
Opioid Rate
197
Opioid Claims
$1,605
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
Brand: 2,213 claims · $1.3M
Generic: 18,031 claims · $264K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Dulaglutide | 161 | $176K |
| Empagliflozin/Metformin Hcl | 140 | $142K |
| Apixaban | 94 | $85K |
| Dapagliflozin Propanediol | 78 | $80K |
| Empagliflozin | 48 | $72K |
| Insulin Glargine,hum.Rec.Anlog | 101 | $58K |
| Levothyroxine Sodium | 457 | $53K |
| Sitagliptin Phos/Metformin Hcl | 36 | $46K |
| Empagliflozin/Metformin Hcl | 58 | $46K |
| Empaglifloz/Linaglip/Metformin | 33 | $37K |
| Rivaroxaban | 24 | $35K |
| Sitagliptin Phos/Metformin Hcl | 21 | $26K |
| Budesonide/Formoterol Fumarate | 60 | $23K |
| Dapaglifloz Propaned/Metformin | 21 | $22K |
| Sitagliptin Phosphate | 17 | $22K |
Prescribing Profile
Patient Profile
70
Avg Age
63%
Female
1.62
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data